For research use only. Not for therapeutic Use.
Tonabersat (Cat.No:I002283) is a small molecule drug under investigation for the treatment of migraine and epilepsy. It acts as a selective blocker of gap junctions, preventing the spread of electrical signals between cells in the brain. Tonabersat has shown promise in clinical trials for reducing the frequency and severity of migraine attacks.
| Catalog Number | I002283 |
| CAS Number | 175013-84-0 |
| Synonyms | SB-220453 |
| Molecular Formula | C20H19ClFNO4 |
| Purity | ≥95% |
| Target | Gap Junction Protein |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | N-[(3S,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-chloro-4-fluorobenzamide |
| InChI | InChI=1S/C20H19ClFNO4/c1-10(24)11-5-7-16-13(8-11)17(18(25)20(2,3)27-16)23-19(26)12-4-6-15(22)14(21)9-12/h4-9,17-18,25H,1-3H3,(H,23,26)/t17-,18-/m0/s1 |
| InChIKey | XLIIRNOPGJTBJD-ROUUACIJSA-N |
| SMILES | CC(C1=CC=C2C([C@H](NC(C3=CC=C(F)C(Cl)=C3)=O)[C@H](O)C(C)(C)O2)=C1)=O |
| Reference | </br>1:Tonabersat for migraine prophylaxis: a systematic review. Cao Y, Zheng OJ.Pain Physician. 2014 Jan-Feb;17(1):1-8. Review. PMID: 24452641 Free Article</br>2:Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura. Garza I.Curr Neurol Neurosci Rep. 2010 Jan;10(1):7-9. doi: 10.1007/s11910-009-0083-9. No abstract available. PMID: 20425219 </br>3:Tonabersat, a novel gap-junction modulator for the prevention of migraine. Silberstein SD.Cephalalgia. 2009 Nov;29 Suppl 2:28-35. doi: 10.1111/j.1468-2982.2009.01973.x. Review. PMID: 19723123 </br>4:Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Silberstein SD, Schoenen J, Göbel H, Diener HC, Elkind AH, Klapper JA, Howard RA.Cephalalgia. 2009 Nov;29 Suppl 2:17-27. doi: 10.1111/j.1468-2982.2009.01974.x. PMID: 19723122 </br>5:Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Dahlöf CG, Hauge AW, Olesen J.Cephalalgia. 2009 Nov;29 Suppl 2:7-16. doi: 10.1111/j.1468-2982.2009.01975.x. PMID: 19723121 </br>6:Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. Durham PL, Garrett FG.Cephalalgia. 2009 Nov;29 Suppl 2:1-6. doi: 10.1111/j.1468-2982.2009.01976.x. Review. PMID: 19723120 Free PMC Article</br>7:Tonabersat for migraine prevention: new life or last gasp? Dodick DW.Lancet Neurol. 2009 Aug;8(8):693-5. doi: 10.1016/S1474-4422(09)70174-7. Epub 2009 Jun 29. No abstract available. PMID: 19570718 </br>8:Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J.Lancet Neurol. 2009 Aug;8(8):718-23. doi: 10.1016/S1474-4422(09)70135-8. Epub 2009 Jun 29. PMID: 19570717 </br>9:Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG; Tonabersat TON-01-05 Study Group..Cephalalgia. 2009 Jul;29(7):742-50. doi: 10.1111/j.1468-2982.2008.01804.x. Epub 2009 Feb 13. PMID: 19222510 </br>10:Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Damodaram S, Thalakoti S, Freeman SE, Garrett FG, Durham PL.Headache. 2009 Jan;49(1):5-20. doi: 10.1111/j.1526-4610.2008.01262.x. PMID: 19125874 Free PMC Article |
